Drug General Information (ID: DDIYMB9KS7)
Drug Name			Bevacizumab		Drug Info		Panitumumab		Drug Info
Drug Type		Monoclonal antibody				Monoclonal antibody
Therapeutic Class		Vegf/Vegfr Inhibitors				Antineoplastics

Mechanism of Bevacizumab-Panitumumab Interaction (Severity Level: Major)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Bevacizumab				Panitumumab
Mechanism		Increase adverse effects and reduce survival time in combination with Panitumumab				Panitumumab
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Panitumumab and Bevacizumab

Recommended Action
Management		The use of panitumumab in combination with bevacizumab and chemotherapy should generally be avoided.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports."
3	Product Information. Vectibix (panitumumab). Amgen USA, Thousand Oaks, CA.